Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 3431-3435, July 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connor, J.
Right arrow Articles by Huang, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connor, J.
Right arrow Articles by Huang, L.

pH-sensitive Immunoliposomes as an Efficient and Target-specific Carrier for Antitumor Drugs1

Jerome Connor and Leaf Huang2

Department of Biochemistry, University of Tennessee, Knoxville, Tennessee 37996-0840

pH-sensitive immunoliposomes composed of dioleoylphosphatidylethanolamine and oleic acid (8:2) significantly enhanced the cytotoxic effect of the entrapped drug 1-ß-D-arabinofuranosylcytosine (ara-C) to target L-929 cells, as compared to free drug, drug encapsulated in antibody-free liposomes, or in pH-insensitive immunoliposomes. These pH-sensitive immunoliposomes were ineffective against nontarget A-31 cells. The enhanced cytotoxic effect could be blocked by excess free antibody or excess drug-free immunoliposomes. Pretreatment of target cells with the weak bases chloroquine or NH4Cl, which raise the internal pH of cellular acidic organelles such as endosomes and lysosomes, inhibited the cell killing activity of ara-C encapsulated in the pH-sensitive immunoliposomes. Since it is known that ara-C is rapidly inactivated in the lysosomes, our results suggest that the release of ara-C from the pH-sensitive immunoliposomes occurs in a prelysosomal compartment, i.e., the endosome. Parallel experiments using methotrexate as a cytotoxic drug confirm the enhanced ability of the pH-sensitive liposomes for cytoplasmic drug delivery over that of free drug. These results indicate that pH-sensitive immunoliposomes can be used as an efficient and target-specific carrier for antitumor drugs.

1 Supported by NIH Grant CA 24553.

2 Research Career Development Awardee (CA 00718). To whom requests for reprints should be addressed.

Received 11/ 4/85. Revised 1/29/86. Accepted 4/ 7/86.




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
X. Wu and Q.-T. Li
Ca2+-induced fusion of sulfatide-containing phosphatidylethanolamine small unilamellar vesicles
J. Lipid Res., July 1, 1999; 40(7): 1254 - 1262.
[Abstract] [Full Text]


Home page
Journal of Bioactive and Compatible PolymersHome page
T. Sato, J. Sunamoto, N. Ishii, and T. Koji
Polysaccharide-Coated Immunoliposomes Bearing Anti-CEA Fab' Fragment and Their Internalization by CEA-Producing Tumor Cells
Journal of Bioactive and Compatible Polymers, January 1, 1988; 3(3): 195 - 204.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.